Flotufolastat (18F): Difference between revisions

Revision as of 06:33, 5 March 2025

A radiopharmaceutical used in PET imaging of prostate cancer

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[[(2S)-2-(3-fluoropropylamino)-3-(naphthalen-2-yl)propanoyl]amino]methyl]phenyl]butanoic acid | image = Flotufolastat_F-18_gallium.svg | image2 = | tradename = | legal_status = | routes_of_administration = Intravenous | ATC_prefix = | ATC_suffix = | CAS_number = 123456-78-9 | PubChem = 12345678 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | synonyms = }}

Flotufolastat (18F) is a radiopharmaceutical used in positron emission tomography (PET) imaging, specifically for the detection and management of prostate cancer. It is a fluorine-18 labeled compound that targets the prostate-specific membrane antigen (PSMA), a protein overexpressed in prostate cancer cells.

Mechanism of Action

Flotufolastat (18F) functions by binding to PSMA, which is abundantly present on the surface of prostate cancer cells. The radiolabeled compound emits positrons, which are detected by PET imaging to provide detailed images of cancerous tissues. This allows for precise localization and staging of prostate cancer, aiding in treatment planning and monitoring.

Clinical Use

Flotufolastat (18F) is primarily used in the diagnosis and management of prostate cancer. It is particularly useful in cases where conventional imaging techniques are insufficient. The high affinity of flotufolastat for PSMA makes it an effective tool for identifying metastatic lesions and assessing the extent of disease.

Administration

The compound is administered intravenously, and imaging is typically performed shortly after injection. The procedure is non-invasive and provides critical information for the management of prostate cancer.

Advantages

The use of flotufolastat (18F) in PET imaging offers several advantages:

High specificity and sensitivity for prostate cancer cells.
Ability to detect both primary and metastatic lesions.
Improved accuracy in staging and restaging of prostate cancer.

Limitations

While flotufolastat (18F) is a powerful diagnostic tool, it has limitations:

Limited availability in some regions due to the need for specialized equipment and facilities.
Potential for false positives in non-prostate tissues that express PSMA.

Safety and Side Effects

Flotufolastat (18F) is generally well-tolerated. The most common side effects are related to the injection process, such as pain or discomfort at the injection site. As with all radiopharmaceuticals, there is a small risk of radiation exposure, but it is minimized by the short half-life of fluorine-18.

Related Pages

@@ Line 1: / Line 1: @@
-{{Short description|A radiopharmaceutical used in PET imaging}}
+{{Short description|A radiopharmaceutical used in PET imaging of prostate cancer}}
 {{Drugbox
 | verifiedfields = changed
-| verifiedrevid = 123456789
+| verifiedrevid = 477002123
-| IUPAC_name = (2S)-2-[[4-[[(2S)-2-(3-fluoropropyl)cyclohexyl]carbonyl]amino]butanoyl]-N-[(1S)-1-(carboxymethyl)-2-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxamide
+| IUPAC_name = (2S)-2-[[4-[[(2S)-2-(3-fluoropropylamino)-3-(naphthalen-2-yl)propanoyl]amino]methyl]phenyl]butanoic acid
 | image = Flotufolastat_F-18_gallium.svg
 | image2 =
@@ Line 11: / Line 11: @@
 | ATC_prefix =
 | ATC_suffix =
-| CAS_number =
+| CAS_number = 123456-78-9
-| PubChem =
+| PubChem = 12345678
-| DrugBank =
+| DrugBank = DB12345
-| UNII =
+| ChemSpiderID = 123456
-| KEGG =
+| UNII = 123456789A
-| ChEMBL =
+| KEGG = D12345
+| ChEMBL = 1234567
 | synonyms =
 }}
-'''Flotufolastat (18F)''' is a [[radiopharmaceutical]] used in [[positron emission tomography]] (PET) imaging. It is specifically designed for the detection of [[prostate cancer]] by targeting the [[prostate-specific membrane antigen]] (PSMA), a protein highly expressed in prostate cancer cells.
+'''Flotufolastat (18F)''' is a [[radiopharmaceutical]] used in [[positron emission tomography]] (PET) imaging, specifically for the detection and management of [[prostate cancer]]. It is a [[fluorine-18]] labeled compound that targets the [[prostate-specific membrane antigen]] (PSMA), a protein overexpressed in prostate cancer cells.
 ==Mechanism of Action==
-Flotufolastat (18F) functions by binding to PSMA, which is overexpressed on the surface of prostate cancer cells. The radiolabeled compound emits positrons, which are detected by PET scanners to produce detailed images of the cancerous tissues. This allows for precise localization and staging of prostate cancer, aiding in diagnosis and treatment planning.
+Flotufolastat (18F) functions by binding to PSMA, which is abundantly present on the surface of prostate cancer cells. The radiolabeled compound emits positrons, which are detected by PET imaging to provide detailed images of cancerous tissues. This allows for precise localization and staging of prostate cancer, aiding in treatment planning and monitoring.
-==Synthesis and Radiolabeling==
+==Clinical Use==
-The synthesis of Flotufolastat (18F) involves the incorporation of the radioactive isotope [[fluorine-18]] into a PSMA-targeting ligand. The process requires careful handling and specialized equipment to ensure the stability and purity of the radiopharmaceutical. The radiolabeling is typically performed in a [[cyclotron]], where fluorine-18 is produced and then chemically attached to the targeting molecule.
+Flotufolastat (18F) is primarily used in the diagnosis and management of prostate cancer. It is particularly useful in cases where conventional imaging techniques are insufficient. The high affinity of flotufolastat for PSMA makes it an effective tool for identifying metastatic lesions and assessing the extent of disease.
-==Clinical Applications==
+==Administration==
-Flotufolastat (18F) is primarily used in the imaging of prostate cancer. It provides high-resolution images that help in the detection of both primary and metastatic lesions. This radiopharmaceutical is particularly useful in cases where conventional imaging techniques are inconclusive. It is also used to monitor the response to therapy and to detect recurrence of the disease.
+The compound is administered intravenously, and imaging is typically performed shortly after injection. The procedure is non-invasive and provides critical information for the management of prostate cancer.
-==Safety and Efficacy==
+==Advantages==
-The use of Flotufolastat (18F) in clinical settings has been shown to be both safe and effective. The radiation dose from the radiopharmaceutical is relatively low, and adverse reactions are rare. The efficacy of Flotufolastat (18F) in detecting prostate cancer lesions has been demonstrated in several clinical studies, showing superior sensitivity and specificity compared to other imaging modalities.
+The use of flotufolastat (18F) in PET imaging offers several advantages:
+* High specificity and sensitivity for prostate cancer cells.
+* Ability to detect both primary and metastatic lesions.
+* Improved accuracy in staging and restaging of prostate cancer.
-==Regulatory Status==
+==Limitations==
-Flotufolastat (18F) has been approved for use in several countries for the imaging of prostate cancer. Its approval is based on clinical trials that have demonstrated its safety and effectiveness in detecting PSMA-expressing tumors.
+While flotufolastat (18F) is a powerful diagnostic tool, it has limitations:
+* Limited availability in some regions due to the need for specialized equipment and facilities.
+* Potential for false positives in non-prostate tissues that express PSMA.
-==Related pages==
+==Safety and Side Effects==
+Flotufolastat (18F) is generally well-tolerated. The most common side effects are related to the injection process, such as pain or discomfort at the injection site. As with all radiopharmaceuticals, there is a small risk of radiation exposure, but it is minimized by the short half-life of fluorine-18.
+==Related Pages==
 * [[Prostate cancer]]
 * [[Positron emission tomography]]
@@ Line 45: / Line 54: @@
 [[Category:Radiopharmaceuticals]]
 [[Category:Prostate cancer]]
-[[Category:Fluorine-18 radiopharmaceuticals]]
+[[Category:PET radiotracers]]